As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
HOME > ORGANIZATION
ORGANIZATION
- Boehringer’s Thorsten Poehl Named EFPIA Japan Vice Chairman
October 31, 2017
- Global Pharma CEOs Prod Japan to Keep Pro-Innovation Policy, Sound Alarm on Proposed PMP Review
October 31, 2017
- PhRMA, EFPIA Upping Lobbying Campaigns amid Drug Pricing Overhaul
October 30, 2017
- JPMA Reprimands Bayer over Side Effect Reporting Violation, Chides “Inappropriate” Promotion
October 20, 2017
- Securities Analysts Rank Shionogi No. 1 among Drug Markers for “Excellence in Disclosure”
October 17, 2017
- JMA President Yokokura Heads WMA
October 17, 2017
- OTC Switching of Emergency Contraceptive Levonorgestrel Will Be Difficult Under Current System: JPA
October 16, 2017
- Taskforce Discussing Info-Sharing Between Drug Makers in Non-Competitive Fields: JPMA R&D Head
October 12, 2017
- Generic Use Rate at 67.8% in April-June: JGA
September 29, 2017
- Biologics Training Center to Start Human Resources Development in Biologics Field Next April
September 20, 2017
- Industry Wants Continued Dialogue to Keep Price Maintenance Premium in Place: Janssen Japan Chief
September 13, 2017
- Daiichi Sankyo’s Hirano to Replace Kamoya as Chuikyo Pharma Rep
September 11, 2017
- Plasma Fraction Products Should Remain in List of Essential Drugs: Blood Products Association Exec
September 11, 2017
- Introduce Permanent Price Maintenance Scheme, Don’t Rush on CEA Debate: UA Zensen
September 7, 2017
- JMA’s Imamura Questions Distribution Coefficient in Cost Calculation Formula
September 5, 2017
- LINK-J Expanding Free Consultation Service for Academic Researchers
August 31, 2017
- Cancer Advocate Warns of Lack of Patient Involvement in CEA Debates
August 30, 2017
- Impact of Drug Price Revisions on Company Management Unclear: JMA Think Tank
August 22, 2017
- JPWA Member Firms Suffer Record 3.5% Sales Fall on Drop-Off in Demand for Hepatitis C Meds
August 16, 2017
- Science Council of Japan Calls for Public-Private Partnerships to Spur Development of Psychiatric Disease Treatments
August 9, 2017
ページ
While grappling with sluggish revenues in Japan last year amid 1.7% negative market growth as put by IQVIA, mega pharma companies saw their upbeat oncology franchises increasingly buttress their businesses in the country, helping them soften the blows from generic…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…